Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
107.32 x 4 107.59 x 5
Post-market by (Cboe BZX)
107.62 -2.08 (-1.90%) 03/28/25 [NASDAQ]
107.32 x 4 107.59 x 5
Post-market 107.62 unch (unch) 16:02 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
106.43
Day High
109.82
Open 108.91
Previous Close 109.70 109.70
Volume 68,200 68,200
Avg Vol 135,170 135,170
Stochastic %K 47.87% 47.87%
Weighted Alpha +28.88 +28.88
5-Day Change -0.53 (-0.49%) -0.53 (-0.49%)
52-Week Range 67.72 - 129.90 67.72 - 129.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,072,222
  • Shares Outstanding, K 19,255
  • Annual Sales, $ 167,130 K
  • Annual Income, $ -4,030 K
  • EBIT $ 10 M
  • EBITDA $ 45 M
  • 60-Month Beta 1.12
  • Price/Sales 12.64
  • Price/Cash Flow 68.27
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 47.34% ( +3.74%)
  • Historical Volatility 46.77%
  • IV Percentile 85%
  • IV Rank 67.86%
  • IV High 54.02% on 11/01/24
  • IV Low 33.22% on 05/09/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 15
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 389
  • Open Int (30-Day) 482

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.14
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate 0.10
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -82.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.43 +4.05%
on 03/13/25
Period Open: 122.23
125.17 -14.02%
on 03/03/25
-14.61 (-11.95%)
since 02/28/25
3-Month
102.79 +4.70%
on 01/13/25
Period Open: 109.19
125.17 -14.02%
on 03/03/25
-1.57 (-1.44%)
since 12/27/24
52-Week
67.72 +58.92%
on 04/22/24
Period Open: 73.10
129.90 -17.15%
on 11/07/24
+34.52 (+47.22%)
since 03/28/24

Most Recent Stories

More News
Ligand to Participate in March Investor Conferences

LGND : 107.62 (-1.90%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND : 107.62 (-1.90%)
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND : 107.62 (-1.90%)
Insider Sale: Director at $LGND (LGND) Sells 2,406 Shares

JOHN L LAMATTINA, a director at $LGND ($LGND), sold 2,406 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.5% of their shares....

LGND : 107.62 (-1.90%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 107.62 (-1.90%)
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

KNSA : 23.09 (-1.16%)
LGND : 107.62 (-1.90%)
SCI : 79.79 (-0.51%)
VBR : 185.58 (-1.76%)
VKTX : 25.65 (-1.84%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 107.62 (-1.90%)
3 Magnificent Growth Stocks to Buy Hand Over Fist

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

LGND : 107.62 (-1.90%)
AGEN : 1.6000 (-3.61%)
CGC : 0.9856 (-6.13%)
CURLF : 1.0000 (+0.74%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

LGND : 107.62 (-1.90%)
TVTX : 19.68 (-3.39%)
VKTX : 25.65 (-1.84%)
NOVN : 0.0941 (-24.84%)
NVS : 112.57 (+1.05%)
ANEB : 1.3600 (-2.86%)
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call...

LGND : 107.62 (-1.90%)
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.

OABI : 2.42 (-2.02%)
LGND : 107.62 (-1.90%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 107.62 (-1.90%)
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business updates. These...

LGND : 107.62 (-1.90%)
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA)...

LGND : 107.62 (-1.90%)
TVTX : 19.68 (-3.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 112.87
2nd Resistance Point 111.35
1st Resistance Point 109.48
Last Price 107.62
1st Support Level 106.09
2nd Support Level 104.57
3rd Support Level 102.70

See More

52-Week High 129.90
Last Price 107.62
Fibonacci 61.8% 106.15
Fibonacci 50% 98.81
Fibonacci 38.2% 91.47
52-Week Low 67.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies